Recent Updates
Recently added Catalysts
NTLA

Intellia Therapeutics to Present at August Healthcare Investor Conference

Tuesday, July 30, 2019 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following upcoming healthcare con

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
9.6%
average across 8 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
NTLA-2002
Phase 3 · Hereditary Angioedema

Full Press Release Details

CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following upcoming healthcare conference in August:
Wednesday, August 7, 2019
SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference
Location: Boston, MA
About Intellia Therapeutics
lina.li@intelliatx.com
Jennifer Mound Smoter
ShareAdd on Google
Tags: NTLA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jul 30, 2019

Biotech snapshot

Cash runway
$628M liquidity · $28M/mo burn
~22 mo
Low dilution risk
Lead asset
NTLA-2002Phase 3
Hereditary Angioedema →

Catalyst track record

+76%
best trade around NTLA's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for NTLA.

See every catalyst's timing & PoA →